Literature DB >> 17045251

Retinal glial cell responses and Fas/FasL activation in rats with chronic ocular hypertension.

Kwang Ro Ju1, Hwa Sun Kim, Jie Hyun Kim, Na Young Lee, Chan Kee Park.   

Abstract

Responses in the retina post injury provoke glial reactions that are not completely understood. This study investigated the reaction of retinal glial cells and the expression and localization of the Fas and Fas-ligand (FasL) in rats with chronic ocular hypertension. Experimental glaucoma was induced in one eye of 60 Sprague-Dawley rats by cauterizing three episcleral vessels. It caused a moderate intraocular pressure (IOP) elevation and significant retinal ganglion cell (RGC) loss for at least 6 weeks in all animals. Immunohistochemical analysis revealed that the expression of GFAP and OX-42 increased in the injured retinae. Fas/FasL immunoreactivity was elevated in the microglia, and we also observed an incremental increase in Fas associated death domain (FADD) immunoreactivity in Müller glial cells and RGCs in the IOP-elevated retinae. The activation of glial cells and upregulation of Fas and FasL suggest that glial cells may contribute to Fas-mediated cell death in the neurodegeneration process of chronic ocular hypertensive retinal insult.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17045251     DOI: 10.1016/j.brainres.2006.09.022

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

1.  Retinal and Optic Nerve Damage is Associated with Early Glial Responses in an Experimental Autoimmune Glaucoma Model.

Authors:  Rozina Noristani; Sandra Kuehn; Gesa Stute; Sabrina Reinehr; Mathias Stellbogen; H Burkhard Dick; Stephanie C Joachim
Journal:  J Mol Neurosci       Date:  2016-01-08       Impact factor: 3.444

Review 2.  Mechanisms of retinal ganglion cell injury and defense in glaucoma.

Authors:  Juan Qu; Danyi Wang; Cynthia L Grosskreutz
Journal:  Exp Eye Res       Date:  2010-04-13       Impact factor: 3.467

3.  Overexpression of Soluble Fas Ligand following Adeno-Associated Virus Gene Therapy Prevents Retinal Ganglion Cell Death in Chronic and Acute Murine Models of Glaucoma.

Authors:  Anitha Krishnan; Fei Fei; Alexander Jones; Patricia Busto; Ann Marshak-Rothstein; Bruce R Ksander; Meredith Gregory-Ksander
Journal:  J Immunol       Date:  2016-11-14       Impact factor: 5.422

4.  Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline.

Authors:  Hani Levkovitch-Verbin; Oriel Spierer; Shelly Vander; Rima Dardik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-13       Impact factor: 3.117

Review 5.  The immune response in glaucoma: a perspective on the roles of oxidative stress.

Authors:  Gülgün Tezel
Journal:  Exp Eye Res       Date:  2010-08-13       Impact factor: 3.467

Review 6.  Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models.

Authors:  Elaine C Johnson; Ying Guo; William O Cepurna; John C Morrison
Journal:  Exp Eye Res       Date:  2009-02-14       Impact factor: 3.467

7.  Changes in ocular aquaporin expression following optic nerve crush.

Authors:  Adnan Dibas; Hidehiro Oku; Masayuki Fukuhara; Takuji Kurimoto; Tsunehiko Ikeda; Rajkumar V Patil; Najam A Sharif; Thomas Yorio
Journal:  Mol Vis       Date:  2010-03-03       Impact factor: 2.367

8.  Spatiotemporal changes in NFATc4 expression of retinal ganglion cells after light-induced damage.

Authors:  Yue Xu; Lu Yang; Shanshan Yu; Qinmeng Shu; Cheng Yang; Jiawei Wang; Fan Xu; Aimin Sang; Xiaoling Liang
Journal:  J Mol Neurosci       Date:  2013-12-21       Impact factor: 3.444

9.  Contribution of TRPV1 to microglia-derived IL-6 and NFkappaB translocation with elevated hydrostatic pressure.

Authors:  Rebecca M Sappington; David J Calkins
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-24       Impact factor: 4.799

10.  Axonal/glial upregulation of EphB/ephrin-B signaling in mouse experimental ocular hypertension.

Authors:  Christine T Fu; Tony Tran; David Sretavan
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.